SYMPOSIA
DAY 1 – 5 December, 2022
11:45 > 12:45 a.m
PARALLEL SESSION N°1
SYMPOSIUM 1 - Effects of electronic cigarettes on smoking cessation in smokers with no plans to quit
Chair: Martin Dockrell, Office for Health Improvement and Disparities
________________________________
Effect of Electronic Cigarettes on Cigarette Abstinence in Smokers With No Plans to Quit: Exploratory Analysis of a Randomized Placebo-Controlled Trial
> Jonathan Foulds, Penn State College of Medicine
Association of Electronic Cigarette Use With Discontinuation of Cigarette Smoking Among Adult Smokers Who Were Initially Never Planning to Quit
> Karin Kasza, Roswell Park Comprehensive Cancer Center
Do the associations between the use of electronic cigarettes and smoking reduction or cessation attempt persist after several years of use? Longitudinal analyses in smokers of the CONSTANCES cohort
> Guillaume Airagnes, University of Paris
SYMPOSIUM 2 - JATC2 (second Joint Action on Tobacco Control): strategies and expected outcomes about evaluation of use, abuse potential and health risks for e-cigarettes and other novel tobacco products in the European Union
Chair: Jérémie Achille, French National Food Safety Agency
________________________________
To evaluate the use, abuse potential and health risks of novel tobacco products and e-cigarettes
> Jérémie Achille, French National Food Safety Agency
Regulation of electronic cigarettes and novel tobacco products in EU Member States
> Olga Caratier, Public Health Agency of Sweden
Investigations regarding e-cigarettes and novel tobacco products awareness, use and perceptions
> Silvano Gallus, Instituto di Ricerche Farmacologiche Mario Negri IRCCS
> Marco Scala, Instituto di Ricerche Farmacologiche Mario Negri IRCCS
DAY 2 – 6 December, 2022
11:45 > 12:45 p.m
PARALLEL SESSION N°3
SYMPOSIUM 3 - Public report and recommendations of the High Council of Public Health (Haut conseil de la santé publique), France on the benefit/risk profile of electronic cigarettes
Chairs: François Alla, University of Bordeaux & Ivan Berlin, APHP
________________________________
Are ENDS an aid to quit smoking and what can be its role in a global smoking cessation strategy? Can these products be considered as risk reduction tools?
> Ivan Berlin, APHP
Recommendations of the French High Council of Public Health, France (HCPH) on the benefit/risk profile of electronic cigarettes among specific groups of smokers
> Anne-Laurence Le Faou, APHP
Is there a risk that ENDS encourage a renormalization of tobacco consumption in France?
> Karine Gallopel-Morvan, EHESP
Is ENDS use a gateway for becoming a smoker among youths?
> François Alla, University of Bordeaux
2:15 > 3:30 p.m
PARALLEL SESSION N°4
SYMPOSIUM 4 - Health effects of vaping - a comprehensive systematic review
Chair: Ann McNeill, King's College London
________________________________
Methods and health risks of nicotine and flavourings
> Debbie Robson, King's College London
Biomarkers of exposure
> Eve Taylor, King's College London
Cancer, respiratory and cardiovascular diseases (CVD)
> Leonie Brose, King's College London
Overview of methodological limitations when assessing vaping effects on health biomarkers
> Erikas Simonavičius, King's College London